Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
55/100
Gabapentin was the most common medication and was associated with 33.0% of polypharmacy-days.
-
55/100
Totally 30,332 patients (5.6%) were diagnosed with dementia during the follow-up, with 14,097 men (4.9%) and 16,235 women (6.5%).
-
55/100
Atrial fibrillation (AF) is one of the cardiovascular risk factors for dementia.
-
Patients on galantamine had longer mean persistence and better adherence compared with patients on donepezil, with a hazard ratio for discontinuation of 0.91 [95% confidence interval (CI) 0.87-0.96] and a relative risk for good adherence of 1.01 (95% CI 1.002-1.03).
-
However, several drugs prescribed for other conditions have been associated with reducing its risk.
-
Idiopathic rapid eye movement (REM) sleep behaviour disorder (IRBD) manifests as unpleasant dreams and vigorous behaviours during REM sleep that can result in injuries.
-
SCarlet RoAD (NCT01224106; WN25203), a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-year study of gantenerumab in prodromal AD, was the first global registration-enabling study using biomarker screening for entry and a single clinical endpoint for outcome.
-
Crenezumab is a humanized anti-abeta monoclonal antibody in development for the treatment of Alzheimer disease (AD).
-
Between January 2006 and December 2010, 20,729 patients aged >70 years received a prescription for an AD medication.
-
55/100
Baseline demographics were similar between the treatment groups.
-
There were no group differences with any of the outcome measures in an intent-to-treat analysis.
-
Misidentification, wandering or agitation, and physical aggression increased during follow-up.
-
Based on reports that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk for Alzheimer's disease (AD), we studied the cross-sectional relation between NSAID use and the risk for AD in a population-based study of disease and disability in older people.
-
To determine if the risk of hip fracture difference between persons receiving benzodiazepines with long (greater than or equal to 24 hours) or short (less than 24 hours) elimination half-lives, we conducted a nested case-control study among residents of the Canadian province of Saskatchewan who were 65 years of age and older.
-
We identified GLP-1 receptor agonist initiation compared to DPP-4 inhibitors initiation was associated with a reduced risk of AD (hazard ratio [HR] ≤ 0.69 and P value < 0.001) and SGLT-2 inhibitor initiation compared to DPP-4 inhibitor initiation was associated with a reduced risk of AD (HR ≤ 0.67 and P value < 0.001).
-
Overall, 74 studies containing 92 cases were found of MDs related to ACHEIs.
-
Due to the continuous aging of the population and consequent increase in dementia, focus on its prevention is of growing importance for public health.
-
The outcomes of the present study aim to elucidate the significance of the PDE4 inhibition mechanism as a prospective therapeutic target for enhancing cognitive function in individuals with (a)MCI and mild AD dementia.
-
In trials of lecanemab, aducanumab, and donanemab, incidence of amyloid-related imaging abnormalities with active treatment ranged from 22% to 44%, the vast majority of which presumably led to unblinding.
-
54/100
Serum concentrations of semorinemab were consistent across studies and showed a dose-proportional increase across the evaluated dose range.
-
The objective of this study was to evaluate the relation of metformin with change in cognition and brain pathology.
-
There was no statistically significant difference between the two groups in terms of depressive symptoms, cognitive functions, and ADL.
-
The use of anticholinergic medications among patients with OAB was associated with an increased risk of new-onset dementia compared to beta-3 agonist users.
-
54/100
Patients who started ChEI therapy after the introduction of the coverage policy had a significantly longer persistence.
-
No statistically significant improvement in the primary outcome measures (MMSE and ADAS-Cog) was observed with drug therapy at 36 weeks, at which point all groups had lost, on average, 1 point on the MMSE and gained 2-3 points on the ADAS-Cog scale compared with baseline.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine
- Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
- Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges
- Exercise as a prescription for patients with various diseases
- Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain
- Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study
- Carbamate as a potential anti-Alzheimer's pharmacophore: A review
- Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force
- [Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 mg, 500 mg for Intravenous Infusion), a novel treatment for Alzheimer's disease]
- Assessing preparedness for Alzheimer disease‐modifying therapies in Australasian health care systems